- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02024425
Functional Bioactive Supplement Effect in Lost Weight Treatment (ALIBIRDII)
A Randomized, Double-blind Trial to Evaluate the Effect of a Functional Bioactive Supplement Associated With a Hypocaloric Equilibrated Diet to Treatment of Obese and Overweight Individuals
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
A randomized, parallel, double-blind, controlled was performed to evaluate the therapeutic effect of a functional bioactive supplement associated with a hypocaloric equilibrated diet to treatment of obesity and overweight.
Women aged between 18 and 65 years with obesity and overweight diagnosis (IMC >25<35 kg/m2) were included in the study. The clinical trial will be performed in the Clinical Nutrition Department of La Paz University Hospital, in Madrid. All of the volunteers will receive a dietetic treatment with 1500 Kcal/day and physical activity recommendations during the study.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
-
Madrid, Spanien, 28061
- Hospital Universitario La Paz
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Women from 45 to 75 years old;
- Overweight (IMC ≥25<30 Kg/m2) or obese (IMC ≥30<35 Kg/m2) volunteers
- Signed informed consent.
Exclusion Criteria:
- Subjects with drug consumption (lipid-lowering, oral hypoglycemic agents and / or hypertensive) in less than one month period;
- Subjects with Diabetes Mellitus insulin dependent;
- Individuals that stop smoking in the next 12 weeks (during the study);
- Subjects with increased alcohol consumption (> 1 glass of vine);
- Subjects that consume drugs, vitamins, minerals, prebiotics or/and probiotics that interfere with the body's response to the extracts in the 2 weeks before to baseline;
- Subjects with drugs consumption special diet due to disease as celiac disease, chronic renal failure, etc;
- Subjects with disorders associated with eating behaviour;
- Subjects with drugs or supplements consumption to weight lost;
- Subjects with physical problems complying with the recommendations of physical activity and diet indicated;
- Subjects who refuse to perform the indicated dietary changes throughout the study;
- Subjects with diseases that could be involucrate in weight lost (not controlled hypothyroidism, serious psychiatric illness, etc.);
- Subjects with mental disease or low cognitive function;
- Subjects with severe diseases (hepatic, kidney, cancer…);
- Pregnant women or lactating;
- Subjects with physical problems complying with the recommendations of physical activity.
- Subjects with intensive physical activity;
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Functional bioactive supplement
The functional bioactive supplement is composed of antioxidant extracted from rosemary, oligosaccharides derived from lactulose and bioactive peptides.
It will be used for obese and overweight treatment
|
1,25g of antioxidant extracted from rosemary, 18g of oligosaccharides derived from lactulosa and 1,25g of bioactive peptides
Andre navne:
|
Placebo komparator: Maltodextrin and saccharose
The control supplement is composed of maltodextrin and saccharose .
It has no effect for obese and overweight treatment
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Changes in body composition
Tidsramme: 12 weeks
|
Clinical response - changes in body composition: weight, waist circumference and Absorptiometry, Dual X-Ray.The primary outcome result measurement was the lost weight, changes in body composition
|
12 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Life style and health status: Life style and physical activity questionnaire
Tidsramme: Week 0 and Week 12
|
Week 0 and Week 12
|
|
Genetic analysis
Tidsramme: Week 0 and Week 12
|
Week 0 and Week 12
|
|
Metabolomic analyses
Tidsramme: Week 0 and Week 12
|
Week 0 and Week 12
|
|
Endothelial function markers
Tidsramme: Week 0 y Week 12
|
Endothelial function markers: eNOS, VCAM-1, PAI1 and blood pressure
|
Week 0 y Week 12
|
Satiety hormones
Tidsramme: Week 0 y Week 12
|
Satiety hormones: ghrelin, GLP-1; Leptin; adiponectin and NPY
|
Week 0 y Week 12
|
Inflammatory markers
Tidsramme: Week 0 and Week 12
|
Inflammatory markers: TNF-α, IL-6, PCR and fibrinogen
|
Week 0 and Week 12
|
Glucose Metabolism
Tidsramme: Week 0 and Week 12
|
Glucose Metabolism: glucose, basal insulin, HbA1c (in diabetic patients), HOMA index (glycemic insulin sensitivity index was calculated using the formula: HOMA-IR = fasting glucose (mmol/l)/fasting immunoreactive insulin (mU/ml)/22•5)
|
Week 0 and Week 12
|
Lipid profile: Cholesterol
Tidsramme: Week 0 and Week 12
|
Lipid profile: Cholesterol, LDL-Cholesterol, HDL-Cholesterol, Triglycerides
|
Week 0 and Week 12
|
Oxidative Stress Parameters
Tidsramme: Week 0 and Week 12
|
Oxidative Stress Parameters: plasma antioxidant capacity (FRAP, ferric reducing antioxidant power) and lipidic peroxidation (TBARS, thiobarbituric acid reactive substances assay), oxidized LDL, PON1, F2-isoprostanes
|
Week 0 and Week 12
|
Adverse effects
Tidsramme: 0 , 3, 6, 9 and 12 weeks
|
Adverse effects: transaminases and creatinine
|
0 , 3, 6, 9 and 12 weeks
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Appetite and satiety
Tidsramme: 0 , 3, 6, 9 and 12 weeks
|
0 , 3, 6, 9 and 12 weeks
|
|
Frequent daily evacuations
Tidsramme: 4 Weeks
|
Frequent daily evacuations, format and consistency of the feces, total and segmental transit time.
The format and consistency of the feces was evaluated in accordance with the Bristol Stool Form Scale (stool are rated based on water content of the feces, with 1 meaning hard stools to 7 meaning liquid stools)
|
4 Weeks
|
Adherence and Tolerance Parameters
Tidsramme: 0 , 3, 6, 9 and 12 weeks
|
Adherence and Tolerance Parameters: adherence and tolerance to the products and diet prescribed
|
0 , 3, 6, 9 and 12 weeks
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Carmen Gomez Candela, PhD, Hospital Universitario La Paz
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ALIBIRDII
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Fedme og overvægt
-
Center for International Blood and Marrow Transplant...Cellular Dynamics International, Inc. - A FUJIFILM CompanyAfsluttetiPS Cell Manufacturing and Banking
-
Istituto Clinico HumanitasAfsluttetGnRH Trigger and Rescue Protocol
-
University of PittsburghNational Institute of Dental and Craniofacial Research (NIDCR); Kaiser...AfsluttetPit-and-fissure tætningsmidlerForenede Stater
-
Gangnam Severance HospitalAfsluttetAnterior Cervical Discectomy and Fusion (ACDF) kirurgiKorea, Republikken
-
Cingulate TherapeuticsAfsluttetSunde frivillige i Fed and Fasted StateForenede Stater
-
University of ArkansasAfsluttetAnterior Cervical Discectomy and Fusion (ACDF)Forenede Stater
-
Weill Medical College of Cornell UniversityIthaca CollegeIkke rekrutterer endnuTransitioning Voice of Transgender and Gender Diverse PeopleForenede Stater
-
Cairo UniversityUkendtSingeleton Conceived Fresh and Frozen Embryo Transfer (ICSI/IVF), naturligt udtænktEgypten
-
Abdul Latif Jameel Poverty Action LabCenters for Medicare and Medicaid Services; General Services Administration...Trukket tilbageLevering af sundhedspleje | Økonomi | Svig | Sundhedsudgifter | Centers for Medicare and Medicaid Services (USA) | Udskrivning
-
Mundipharma Research LimitedAfsluttetACOS (Fixed Airflow Obstruction and Elevated Eosinophils)Slovakiet
Kliniske forsøg med Functional bioactive supplement
-
Medical Research CouncilUkendtSelvskadende adfærdDet Forenede Kongerige
-
IRCCS Eugenio MedeaRekrutteringFor tidlig fødsel | Forældre-barn relationerItalien
-
Milton S. Hershey Medical CenterRekrutteringMobilitetsbegrænsning | Gå, besværForenede Stater
-
Recep Tayyip Erdogan University Training and Research...AfsluttetMuskelstyrke | Sportsskade | MuskelkontraktionKalkun
-
University of BeykentAfsluttet
-
Washington University School of MedicineMerck Sharp & Dohme LLCAfsluttet
-
The Institute for Functional MedicineFunctional Medicine Coaching AcademyAfsluttet
-
NorthShore University HealthSystemAnn & Robert H Lurie Children's Hospital of Chicago; Northwestern University... og andre samarbejdspartnereAfsluttetFor tidligt fødte spædbørn med ekstremt lav fødselsvægt | Niveauer af flerumættede fedtsyrerForenede Stater
-
Prince of Songkla UniversityAfsluttetHoved- og halskræftThailand
-
Société des Produits Nestlé (SPN)AfsluttetProbiotisk tilskudFilippinerne